Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

ntly in a Phase 2 study as a therapy for colorectal cancer, and CPX-351, currently in a Phase 1 study for patients with leukemia, these promising results, indicating broad potential anti-tumor activity for CPX-571, represent another validation of Celator's CombiPlex technology platform," said Andrew Janoff, Ph.D., CEO of Celator.

CombiPlex(TM), Celator's proprietary technology platform, identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered to patients.

"Based on these findings, there is significant support to advance CPX-571 to clinical development in the treatment of small cell lung cancers and potentially for use in treating other types of cancer," said Arthur Louie, M.D., Celator's chief medical officer.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX 571, now positioned to advance to Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ... & USA BioSimilar Market Analysis to 2021" report ... Biosimilar market will be initiated in September as Sandoz ... the global market react? Will biosimilars explode into the ... the US economy up to $250 billion within the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased ... present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & ... largest analytical and scientific instruments show which will be held at International Conference ...
(Date:8/28/2015)... ... 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the ... service. Images such as the Fonz in a lab coat and Large Marge have ... humdrum spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer ...
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Neogen acquires U.K.-based Lab M Holdings 2
... may seem obvious that dunking relatively spherical objects in ... will result in an array of completely encapsulated berries. ... have similarly dunked their wares in protective coatings in ... chemical interactions with solvents. Unfortunately, reactions in the ...
... Beta-Pro LLC, announced today that it has expanded ... drug discovery and research institutes in the $2 ... now manages extensive laboratory facilities in the University ... "Beta-Pro has already established a foothold ...
... US Oncology, Inc., the nation,s leading integrated oncology ... patient in a Phase I clinical trial through its ... trials present special challenges, including increased safety concerns, higher ... some first-in-human trials, making Phase I trials more difficult ...
Cached Biology Technology:Nanoscopic particles resist full encapsulation, Sandia simulations show 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... St. Louis, July 31, 2008 Staying awake slows down ... its peak after sleep but inevitably trends downward throughout the ... For the first time, researchers at Washington University School of ... this downward slide. When scientists genetically tweaked a part of ...
... Michigan State University researcher and his students have ... and stronger and could result in more fuel-efficient ... medical and sports equipment. The material ... in the development of new and expanded applications ...
... Auckland, New Zealand - Kiwifruit lovers can look forward ... to the release this week of crucial genetic data ... new varieties with increased health properties and exciting colours ... company HortResearch and listed New Zealand biotech company Genesis ...
Cached Biology News:Brain tweak lets sleep-deprived flies stay sharp 2'Small' research at MSU leads to advances in energy, electronics 2Genetic data promises new future for kiwi fruit 2Genetic data promises new future for kiwi fruit 3
... Digital Sight DS-L2 imaging controller is a ... DS-L1, and allows users to comfortably observe, ... DS-L2 controller features an 8.4 inch LCD ... variety of Nikon cameras including the DS-Fi1 ...
... NovaTaq DNA Polymerase is a premium quality ... This thermostable enzyme is suitable for a ... the highest purity and reproducible performance, each ... of quality control assays. NovaTaq DNA Polymerase ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: